Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

964
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
964
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.2K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.2K
Glaucoma: Overview01:25

Glaucoma: Overview

1.3K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.3K
Blinding01:11

Blinding

3.8K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe Congenital Ptosis Repair: A Report by the American Academy of Ophthalmology.

Ophthalmology·2026
Same author

The Role of Corticosteroids in the Management of Orbital Cellulitis: A Report by the American Academy of Ophthalmology.

Ophthalmology·2026
Same author

Reply.

Ophthalmology science·2026
Same author

Patient perceptions of artificial intelligence in ophthalmology: a cross-sectional survey study.

The British journal of ophthalmology·2026
Same author

Author Response: OphthoACR (Ophthalmology Automated Chart Review): An AI-Powered Tool for Complete Automation of Ophthalmology Chart Reviews and Cohort Data Analysis.

Translational vision science & technology·2026
Same author

LASIK for Hyperopia: A Report by the American Academy of Ophthalmology.

Ophthalmology·2026

Related Experiment Video

Updated: Jan 19, 2026

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

997

Dupilumab-associated blepharoconjunctivitis.

Sefy A Paulose1, Suzanne W Sherman1, Lora R Dagi Glass1

  • 1Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA.

American Journal of Ophthalmology Case Reports
|September 20, 2019
PubMed
Summary
This summary is machine-generated.

Dupilumab, a treatment for atopic dermatitis, can cause eye inflammation like blepharoconjunctivitis. Prompt treatment with eyelid hygiene, topical steroids, and antibiotics effectively manages these ocular side effects.

Keywords:
Atopic dermatitisBlepharoconjunctivitisDupilumabLipiflowOcular side effects

More Related Videos

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
05:00

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Published on: April 1, 2019

15.6K
In Vivo Confocal Microscopy: A Standard Operating Procedure for the Detection of Demodex Mites at the Eyelid Margin
05:21

In Vivo Confocal Microscopy: A Standard Operating Procedure for the Detection of Demodex Mites at the Eyelid Margin

Published on: July 3, 2025

808

Related Experiment Videos

Last Updated: Jan 19, 2026

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

997
Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
05:00

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Published on: April 1, 2019

15.6K
In Vivo Confocal Microscopy: A Standard Operating Procedure for the Detection of Demodex Mites at the Eyelid Margin
05:21

In Vivo Confocal Microscopy: A Standard Operating Procedure for the Detection of Demodex Mites at the Eyelid Margin

Published on: July 3, 2025

808

Area of Science:

  • Ophthalmology
  • Dermatology
  • Immunology

Background:

  • Atopic dermatitis is a chronic inflammatory skin condition.
  • Dupilumab is a biologic therapy targeting atopic dermatitis.
  • Ocular side effects can occur with dupilumab treatment.

Observation:

  • A patient with severe atopic dermatitis developed blepharitis, chalazia, dry eye, and conjunctivitis after initiating dupilumab therapy.
  • Ocular examination revealed meibomian gland dysfunction and significant papillary conjunctivitis.
  • Meibography showed meibomian gland atrophy and bifurcation.

Findings:

  • A treatment regimen combining Cliradex eyelid wipes, Avenova, neomycin/polymyxin B/dexamethasone ophthalmic ointment, and LipiFlow therapy improved visual acuity and reduced ocular discomfort.
  • Consistent eyelid hygiene and topical medications post-infusion were crucial for management.
  • The patient's ocular symptoms resolved within five weeks of initiating the comprehensive treatment plan.

Implications:

  • This case highlights the importance of recognizing and managing dupilumab-associated ocular side effects.
  • A multi-modal approach, including targeted eyelid hygiene and medical therapies, can effectively treat these conditions.
  • Further research into the mechanisms and optimal management of dupilumab-induced ocular surface disease is warranted.